Understanding the evolution of the Chotanagpur Granite Gneiss Complex (CGGC) of the East Indian Shield is crucial to decipher the role of the Indian Shield in the formation of the Rodinia supercontinent. The area around Deoghar–Dumka exposes a suite of granulite-facies orthogneisses (variably retrogressed to amphibole–biotite gneiss) that enclose remnants of Palaeoproterozoic metasedimentary and meta-igneous rocks. Results from mineral chemistry, laser ablation inductively coupled plasma mass spectrometry (LA ICP-MS) U–Pb dating of zircon and limited bulk-rock compositions of the studied rocks suggest that the magmatic protoliths of the felsic orthogneisses had A-type chemistry, and that these were emplaced at approximately 1450 Ma presumably in a continental rift setting. Intense deformation and metamorphism of the felsic rock culminated at approximately 9 kbar and 850°C along an apparent geothermal gradient of 26°C km−1. These peak metamorphic conditions were successively followed by initially a steeply decompressive and then a weakly decompressive retrograde pressure–temperature path. The shape of the retrograde pressure–temperature path and the estimated geothermal gradient at the metamorphic peak are interpreted to be the products of continent–continent collision; U–Pb dates of metamorphic zircon overgrowths suggest an age of approximately 943 Ma for the collisional event. This study demonstrates that ‘Grenville-age’ orogenesis thoroughly reworked the approximately 1450 myr-old basement of the CGGC during the formation of the Rodinia supercontinent.

No abstract

No abstract

No abstract

The development of drug delivery systems with microencapsulated therapeutic agents is a promising approach to the sustained and controlled delivery of various drug molecules. The incorporation of dual release kinetics to such delivery devices further adds to their applicability. Herein, novel core-shell scaffolds composed of sodium deoxycholate and trishydroxymethylaminomethane (NaDC-Tris) have been developed with the aim of delivering two different drugs with variable release rates using the same delivery vehicle. Data obtained from XRD studies, sol-gel transition temperature measurement, rheology and fluorescence studies of the core-shell systems indicate a significant alteration in the core and the shell microstructural properties in a given system as compared to the pure hydrogels of identical compositions. The release of the model drugs Fluorescein (FL) and Rhodamine B (RhB) from the shell and the core, respectively, of the two core-shell designs studied exhibited distinctly different release kinetics. In the 25@250 core-shell system, 100% release of FL from the shell and 19% release of RhB from the core was observed within the first 5 hours, while 24.5 hours was required for the complete release of RhB from the core. For the 100@250 system, similar behaviour was observed with varied release rates and a sigmoidal increase in the core release rate upon disappearance from the shell. Cell viability studies suggested the minimal toxicity of the developed delivery vehicles towards NMuMG and WI-38 cells in the concentration range investigated. The reported core-shell systems composed of a single low molecular weight gelator with dual release kinetics may be designed as per the desired application for the consecutive release of therapeutic agents as required, as well as combination therapy commonly used to treat diseases such as diabetes and cancer.